Robert Straub
Yale University
6 Papers
14 Citations
Robert Straub is an academic researcher from Yale University. The author has contributed to research in topics: Triple-negative breast cancer & Cancer research. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas
Michael Krauthammer,Yong Kong,Antonella Bacchiocchi,Perry Evans,Natapol Pornputtapong,Cen Wu,James P. McCusker,Shuangge Ma,Elaine Cheng,Robert Straub,Merdan Serin,Marcus Bosenberg,Stephan Ariyan,Deepak Narayan,Mario Sznol,Harriet M. Kluger,Shrikant Mane,Joseph Schlessinger,Richard P. Lifton,Ruth Halaban +19 more
TL;DR: It is concluded that NF1 is a key tumor suppressor lost in melanomas, and that concurrent RASopathy gene mutations may enhance its role in melanomagenesis.
392
GNA14 Somatic Mutation Causes Congenital and Sporadic Vascular Tumors by MAPK Activation.
Young H. Lim,Antonella Bacchiocchi,Jingyao Qiu,Robert Straub,Anna L. Bruckner,Lionel Bercovitch,Deepak Narayan,Jennifer M. McNiff,Christine J. Ko,Leslie Robinson-Bostom,Richard J. Antaya,Ruth Halaban,Keith A. Choate +12 more
TL;DR: The findings identify GNA14 mutations as a cause of childhood vascular tumors, offer insight into mechanisms of oncogenic transformation by mutations affecting Gaq family members, and identify potential targets for therapeutic intervention.
132
Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple negative breast and ovarian carcinomas
Francesca Menghi,Kalyan Banda,Pooja Kumar,Robert Straub,Lacey E. Dobrolecki,Isabel Viqueira Rodriguez,Susan E. Yost,Harshpreet Chandok,Marc R. Radke,George Somlo,Yuan Yuan,Michael Lewis,Elizabeth M. Swisher,Edison T. Liu +13 more
TL;DR: It is shown how integrating both the strength of this cancer immune signature and the presence of BRCA mutations results in more accurate predictions of patient response when compared to either HRD status or BrcA status alone.
32
A novel anti-melanoma SRC-family kinase inhibitor.
Ruth Halaban,Antonella Bacchiocchi,Robert Straub,Jian Cao,Mario Sznol,Deepak Narayan,Ahmed A. Allam,Michael Krauthammer,Michael Krauthammer,Tarek S. Mansour +9 more
TL;DR: A new compound, SAB298, that is a SRC-family kinase (SFK) inhibitor that inhibited SRC and PI3K activity, and had the additional property of ERBB2 inhibition, that lead to inactivation of the two ERK phosphatases PP2A and SHP2.
Abstract P1-13-10: Deconvoluting dynamics of acquired chemoresistance in Triple Negative Breast Cancer tumors
Pooja Kumar,Francesca Menghi,Robert Straub,Patience Mukashyaka,Michael Lloyd,Harshpreet Chandok,Joshy George,Jeffery Chuang,Edison T. Liu +8 more
TL;DR: Menghi et al. as discussed by the authors showed that acquired resistance can emerge by enrichment of not one but a composite of multiple preexisting resistant clones, including A25, A33, and CCR.